HUTCHMED (China) Limited (HKG:0013)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Oncology/Immunology - R&D				39.20M	-	-	-	-
Oncology/Immunology - Marketed Products				124.64M	-	-	-	-
Other Ventures				262.57M	236.52M	197.76M	178.10M	172.88M
Other Ventures Growth				11.01%	19.60%	11.04%	3.02%	-
Oncology/Immunology - R&D - PRC				-	43.18M	10.26M	16.03M	37.65M
Oncology/Immunology - R&D - PRC Growth				-	320.79%	-35.97%	-57.43%	4.59%
Oncology/Immunology - Marketed Products - PRC				-	76.43M	19.95M	10.77M	3.59M
Oncology/Immunology - Marketed Products - PRC Growth				-	283.05%	85.33%	200.31%	-
Total				426.41M	356.13M	227.98M	204.89M	214.11M
Total Growth				19.73%	56.21%	11.27%	-4.31%	-11.23%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
People's Republic of China (PRC)				426.41M	-	-	-	-
Total				426.41M	-	-	-	-

Source: S&P Global Market Intelligence.